CluenexAptarGroup ATR
AptarGroup scores average on business quality (5.3 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What AptarGroup does
Aptargroup makes dispensing, sealing, and active packaging systems like pumps and closures that brand owners use for pharma, beauty, and food products. Customers pay for proprietary delivery tech that protects sensitive formulas and drives consumer adoption.
- What it does best
Aptargroup dominates high-end dispensing technology with a gross margin of 36.1% that easily outpaces peers like Ball at 18.6%. This edge stems from patented pump designs and sticky pharma relationships that make switching suppliers risky for brand owners.
- The main risk
Rising debt levels threaten capital flexibility, with net debt climbing to $1.1B. If end-market demand softens further, debt servicing costs will consume a larger share of operating cash flow and pinch buyback capacity.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin stands at 12.4% while FCF margin trails at 7.8%, driven by steady capex demands of $275.0M. Margins remain stable rather than expanding, proving that scaling does not automatically reduce production costs.
Switching costs form its primary moat, locking in pharmaceutical and beauty customers who rely on validated dispensing designs. Its gross margin ranks in the top quartile of its sector at 71st percentile, reflecting strong pricing power.
Revenue grew 5.4% to $3.9B, marking a modest acceleration over past annual periods. This top-line movement reflects steady demand across its packaging segments without explosive volume spikes.
Debt-to-equity sits at 0.6 and interest coverage is 7.7x, leaving debt service manageable. Free cash flow reached $308.0M, showing softer generation compared to historical peaks. Overall, the balance sheet is holding steady.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
5 sold $3.6M outside pre-planned sales.
Our sealed record on ATR
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
AptarGroup scores average on the Cluenex quality check (5.3 of 10), measured against its own industry. Profitability is weak, moat fair, growth slow and financial health fair.
In the last 90 days of SEC Form 4 filings: 5 sold $3.6M outside pre-planned sales.
Oct 29, 2026.
See ATR today
- Today's verdict on ATR, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “AptarGroup (ATR)”, https://cluenex.com/stocks/atr/, data as of Oct 10, 2026.